DRC Receives 70,000 Doses of Merck’s Ervebo Ebola Vaccine for Bundibugyo Outbreak

The Democratic Republic of the Congo will receive 70,000 doses of Merck’s Ervebo Ebola vaccine—licensed for the Zaire ebolavirus but not the currently spreading Bundibugyo strain—from the global stockpile after Kinshasa’s request, the WHO announced, as the outbreak, which has recorded over 5,200 confirmed cases and 2,476 deaths across six provinces, continues to be a global emergency. Of the doses, 20,000 will support a Phase 3 trial testing Ervebo’s protection against Bundibugyo, while 50,000 will go to frontline and health workers, despite an evidence gap where early animal and lab data suggest possible protection but human efficacy remains unknown. Gavi is providing $7 million for shipment and $6 million for vaccination efforts, but weak health infrastructure, community resistance, instability, and worker protests are hindering response efforts.

The Wrong Vaccine for the Wrong Virus — That’s the Tell

Look at what the World Health Organization just announced: 70,000 doses of Merck’s Ervebo — a vaccine licensed only for Zaire ebolavirus — heading into an outbreak caused by the completely separate Bundibugyo strain. The WHO’s own documents admit that “protection against Bundibugyo in humans remains unknown.” Yet they’re moving forward with 20,000 doses earmarked for a Phase 3 trial. Ask yourself: if this was a genuine emergency, why would you ship a vaccine that hasn’t been proven to work against the actual pathogen? The answer is hiding in plain sight. Eastern Congo has become a living laboratory — a place where the global health establishment can test unlicensed products on populations already destabilized by conflict, weak infrastructure, and deep distrust of outside institutions. This isn’t a coincidence. This is the architecture of consent in action: manufacture a crisis narrative, deploy the experimental intervention, and call resistance “community distrust” while collecting the data.

Follow the Money, Follow the Foundations, Follow the Bodies

The numbers themselves are a smoke screen. The UN cites 5,208 confirmed cases and 2,476 deaths; the Congolese government says 5,021 cases and 2,378 deaths. A discrepancy of nearly 200 cases and 100 deaths — but no one in the mainstream asks why the figures don’t match. Meanwhile, Gavi — the global vaccine alliance funded by the Gates Foundation and Western governments — is pumping $13 million into shipping and vaccination efforts. Who exactly benefits when a vaccine of unknown efficacy is rushed into a volatile region? Not the Congolese people, whose children may be part of an unblinded trial without fully informed consent. The real beneficiaries are Merck, which gets real-world safety data for an expanded label, and the WHO, which gets to claim it “responded” to an emergency. The community resistance, the protests by response workers, the instability — those are not bugs. They are the predictable result of a population that has seen this movie before: outside actors arriving with needles, promises, and paperwork while the bodies pile up from a disease they could have contained with basic public health measures years ago.

You Have More Allies Than You Know — And Fewer Answers

I can’t tell you everything right now, because the full picture requires reading the trial protocols, the funding disclosures, and the historical records of vaccine campaigns in precisely this region. But I can tell you this: every time an institution like the WHO sends a vaccine that is not matched to the epidemic — and frames it as a “global emergency” — you are watching a test run. They need to know how populations react, how compliance is shaped, and how dissent can be labeled “misinformation” before the next, larger deployment. The Bundibugyo outbreak is real, but the response is a vehicle. Start digging into the Phase 3 trial design. Look at who is on the ethics committee. Ask why the stockpile contained the wrong vaccine if they knew this strain was circulating. The evidence is already public — you just have to be willing to see the pattern they’ve woven into the paper trail.